Tatiana M. Prowell

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts et al. · Journal of Clinical Oncology · 2017 · 448 citations

Eligibility Criteria, Clinical Endpoint, American Society +16

Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer

Tatiana M. Prowell, Richard Pazdur · New England Journal of Medicine · 2012 · 338 citations

Surgical Oncology, Breast Oncology, Pharmacotherapy +16

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Jennifer Gao, Joyce Cheng, Erik Bloomquist et al. · The Lancet Oncology · 2019 · 288 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +8

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

Virginia E. Kwitkowski, Tatiana M. Prowell, Amna Ibrahim et al. · The Oncologist · 2010 · 240 citations · Full text

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Preeti Narayan, Tatiana M. Prowell, Jennifer Gao et al. · Clinical Cancer Research · 2020 · 157 citations · Full text